Maladie veino-occlusive et hémangiomatose capillaire pulmonaire

Simonneau, 2009, Updated clinical classification of pulmonary hypertension, J Am Coll Cardiol, 54, S43, 10.1016/j.jacc.2009.04.012 Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Respir J 2009; 0: 09031936.00139009v2. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30:2493–537. Montani D, O’Callaghan D, Jaïs X, Savale L, Natali D, Redzepi A et al.. Implementing the ESC/ERS pulmonary hypertension guidelines: real-life cases from a national referral centre. Eur Respir Rev 2009; 18: 114, 231–249. Dorfmuller, 2007, Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases, Hum Pathol, 38, 893, 10.1016/j.humpath.2006.11.022 Rabiller, 2006, Occult alveolar haemorrhage in pulmonary veno-occlusive disease, Eur Respir J, 27, 108, 10.1183/09031936.06.00054105 Resten, 2004, Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease, AJR Am J Roentgenol, 183, 65, 10.2214/ajr.183.1.1830065 Rambihar, 1979, Pulmonary veno-occlusive disease:antemortem diagnosis from roentgenographic and hemodynamic findings, Can Med Assoc J, 120, 1519 Montani, 2008, Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology, Medicine (Baltimore), 87, 220, 10.1097/MD.0b013e31818193bb Montani, 2009, Pulmonary veno-occlusive disease, Eur Respir J, 33, 189, 10.1183/09031936.00090608 Pietra, 2004, Pathologic assessment of vasculopathies in pulmonary hypertension, J Am Coll Cardiol, 43, 25S, 10.1016/j.jacc.2004.02.033 Lantuejoul, 2006, Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: : a clinicopathologic study of 35 cases, Am J Surg Pathol, 30, 850, 10.1097/01.pas.0000209834.69972.e5 Holcomb, 2000, Pulmonary veno-occlusive disease: : a case series and new observations, Chest, 118, 1671, 10.1378/chest.118.6.1671 Mandel, 2000, Pulmonary veno-occlusive disease, Am J Respir Crit Care Med, 162, 1964, 10.1164/ajrccm.162.5.9912045 Souza, 2008, Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases, Eur Respir J, 31, 343, 10.1183/09031936.00104807 Montani D, Jais X, Price LC, Achouh L, Degano B, Mercier O et al. Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. Eur Respir J 2009; 34: doi:10.1183/09031936.00017809. Nunes, 2006, Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis, Thorax, 61, 68, 10.1136/thx.2005.042838 Fartoukh, 2000, Severe pulmonary hypertension in histiocytosis X, Am J Respir Crit Care Med, 161, 216, 10.1164/ajrccm.161.1.9807024 Runo, 2003, Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II, Am J Respir Crit Care Med, 167, 889, 10.1164/rccm.200208-861OC Aldred, 2006, BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension, Hum Mutat, 27, 212, 10.1002/humu.9398 Machado, 2006, Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension, Hum Mutat, 27, 121, 10.1002/humu.20285 Montani, 2009, Idiopathic Pulmonary Arterial Hypertension and Pulmonary Veno-occlusive Disease: Similarities and Differences, Semin Respir Crit Care Med, 30, 411, 10.1055/s-0029-1233310 Sitbon, 2005, Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension, Circulation, 111, 3105, 10.1161/CIRCULATIONAHA.104.488486 Humbert, 2004, Treatment of pulmonary arterial hypertension, N Engl J Med, 351, 1425, 10.1056/NEJMra040291 Montani D, Achouh L, Sitbon O, Simonneau G, Humbert M. Pulmonary venoocclusive disease and failure of specific therapy. Chest 2009;136:1181. Wagenvoort, 1974, The pathology of pulmonary veno-occlusive disease, Virchows Arch A Pathol Anat Histol, 364, 69, 10.1007/BF01230858 Chazova, 2000, Venous and arterial changes in pulmonary veno-occlusive disease, mitral stenosis and fibrosing mediastinitis, Eur Respir J, 15, 116, 10.1183/09031936.00.15111600 Jais, 2008, Management of lupus and mixed connective tissue disease-associated pulmonary arterial hypertension, Arthritis Rheum, 58, 521, 10.1002/art.23303 Sanchez, 2006, Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension, Chest, 130, 182, 10.1378/chest.130.1.182 Montani, 2005, Traitement de l’hypertension artérielle pulmonaire, Presse Med, 34, 1445, 10.1016/S0755-4982(05)84206-X Montani D, Jaïs X, Dorfmüller P, Simonneau G, Sitbon O, Humbert M. Goal-oriented therapy in pulmonary veno-occlusive disease: a word of caution. Eur Respir J 2009; 34:1204–6. Montani, 2009, Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension, Adv Ther, 10.1007/s12325-009-0064-z Okumura, 2002, Effects of continuous IV prostacyclin in a patient with pulmonary veno-occlusive disease, Chest, 122, 1096, 10.1378/chest.122.3.1096 Davis, 1995, Effect of prostacyclin on microvascular pressures in a patient with pulmonary veno-occlusive disease, Chest, 108, 1754, 10.1378/chest.108.6.1754 Hoeper, 1999, Effects of inhaled nitric oxide and aerosolized iloprost in pulmonary veno-occlusive disease, Respir Med, 93, 62, 10.1016/S0954-6111(99)90079-3 Kuroda, 2006, Sildenafil as adjunct therapy to high-dose epoprostenol in a patient with pulmonary veno-occlusive disease, Heart Lung Circ, 15, 139, 10.1016/j.hlc.2005.07.002 Barreto, 2005, One-year follow-up of the effects of sildenafil on pulmonary arterial hypertension and veno-occlusive disease, Braz J Med Biol Res, 38, 185, 10.1590/S0100-879X2005000200006 Almagro, 2002, Pulmonary capillary hemangiomatosis associated with primary pulmonary hypertension: report of 2 new cases and review of 35 cases from the literature, Medicine (Baltimore), 81, 417, 10.1097/00005792-200211000-00002